Table 2 Description of inhaled treatments received by the analysed population, by GOLD ABCD category
From: Are there specific clinical characteristics associated with physician’s treatment choices in COPD?
GOLD A | GOLD B | GOLD C | GOLD D | p-value | |
|---|---|---|---|---|---|
N = 143 | N = 676 | N = 28 | N = 324 | ||
No bronchodilator | 45 (31.5) | 104 (15.4) | 7 (25.0) | 20 (6.2) | < 0.001* |
SABA | 22 (15.4) | 199 (29.5) | 5 (17.9) | 167 (51.4) | < 0.001* |
SAMA | 3 (2.1) | 60 (8.9) | 3 (10.7) | 78 (24.0) | < 0.001* |
SABA or SAMA | 22 (15.4) | 200 (29.6) | 5 (17.9) | 169 (52.0) | < 0.001* |
No SABA nor SAMA | 121 (84.6) | 475 (70.4) | 23 (82.1) | 156 (48.0) | < 0.001* |
Only short-acting bronchodilators | 3 (2.1) | 18 (2.7) | 2 (7.1) | 15 (4.6) | 0,159 |
Any LABA-containing regimen | 72 (50.3) | 446 (66.1) | 17 (60.7) | 276 (84.9) | < 0.001* |
Any LAMA-containing regimen | 66 (46.2) | 436 (64.6) | 11 (39.3) | 235 (72.3) | < 0.001* |
Any ICS-containing regimen | 35 (24.5) | 254 (37.6) | 11 (39.3) | 221 (68.0) | < 0.001* |
LABA alone | 16 (11.2) | 51 (7.6) | 3 (10.7) | 7 (2.2) | < 0.001* |
LAMA alone | 23 (16.1) | 107 (15.9) | 2 (7.1) | 14 (4.3) | < 0.001* |
LABA+LAMA | 21 (14.7) | 143 (21.2) | 3 (10.7) | 50 (15.4) | 0.05* |
LABA+ICS | 13 (9.1) | 66 (9.8) | 5 (17.9) | 48 (14.8) | 0,061 |
LAMA+ICS | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
LABA+LAMA+ICS | 22 (15.4) | 186 (27.6) | 6 (21.4) | 171 (52.6) | < 0.001* |
Therapeutic category | |||||
A | 48 (33.6) | 122 (18.1) | 9 (32.1) | 35 (10.8) | < 0.001* |
B | 39 (27.3) | 158 (23.4) | 5 (17.9) | 21 (6.5) | < 0.001* |
C | 21 (14.7) | 143 (21.2) | 3 (10.7) | 50 (15.4) | 0,057 |
D | 13 (9.1) | 66 (9.8) | 5 (17.9) | 48 (14.8) | 0,061 |
E | 22 (15.4) | 186 (27.6) | 6 (21.4) | 171 (52.6) | < 0.001* |